ORIGINAL ARTICLES

Treatment effect of Zhuang medicine Herba abri formula on hepatic fibrosis induced by Echinococcus multilocularis infection

  • LI Jiajing ,
  • HUANG Wenjun ,
  • CAO Deping
Expand
  • 1 Department of Human Parasitology, Basic Medical College
    2 Key Lab of Pathogenic Biology, Guilin Medical University, Guilin 541199, Guangxi, China

Received date: 2024-05-27

  Revised date: 2024-08-16

  Online published: 2024-10-21

Supported by

Guangxi Natural Science Foundation(2020GXNSFAA297216)

Abstract

Objective To observe the treatment effect of Zhuang medicine Herba abri formula (HaF) on hepatic fibrosis induced by Echinococcus multilocularis infection in vivo and in vitro. Methods The HaF solution was prepared from Zhuang medicine Herba abri capsule commercial available. Human hepatic stellate cell-LX2 (HSC-LX2) were cultured with 25, 50, 100 or 200 µg/ml HaF solution for 72, 96 and 120 h, then the relative expression of α-smooth muscle actin (α-SMA) and collagen Ⅰ in HSC-LX2 was detected with Western blotting, respectively. Separately, HSC-LX2 cells were stimulated with 0.1 mg/ml E. multilocularis crude antigen for 24 h, followed by addition of 100 μg/ml HaF for 24, 48 and 72 h, subsequently, the relative expression of α-smooth muscle actin (α-SMA) and collagen Ⅰ in HSC-LX2 were detected by Western blotting. Thirty-six female Kunming mice were randomly assigned into the following groups: control group (4 mice), infection group (4 mice), HaF treatment groups at doses of 0.5 g/(kg•d) (5 mice), 1.0 g/(kg•d) (5 mice), and 2.0 g/(kg•d) (6 mice), albendazole (ABZ) treatment group (6 mice), and ABZ + HaF combined treatment group (6 mice). The infection group and each treatment group received intraperitoneal injection of 2 000 protoscolices, while the control group was injected with an equal volume of normal saline. After a period of 60 days post-infection, the mice in treatment groups were treated daily by gavage with the corresponding medication for 60 days, and then the mice liver and spleen tissues were collected and weighed to calculate hepatic index and splenic indix. The content of hydroxyproline (HYP) in liver tissue was determined by the alkaline hydrolysis method, and the level of serum aspartate aminotransferase (AST) was measured by the colorimetric method. Western blotting was performed to detect the relative expression of α-SMA and collagen Ⅰ in the liver, while hematoxylin-eosin staining (HE) and Masson staining were used to observe pathological changes in liver and spleen tissues. The comparison between two groups of data was conducted using an independent-samples t-test. Results The relative expression of α-SMA protein and collagen Ⅰ was 0.401 ± 0.218 and 0.352 ± 0.058, respectively, in HSC-LX2 cells treated with 100 µg/ml HaF solution at 96 h, which were significantly lower than those in the control group (1.435 ± 0.297, 1.340 ± 0.416) (t = 2.755, 11.120; both P < 0.05). The control group did not exhibit any statistically significant differences compared to the other concentrations and durations of treatment. Compared to the control group (0.895 ± 0.417, 1.009 ± 0.378), the relative expression levels of α-SMA and collagen Ⅰ in HSC-LX2 treated with HaF for 48 h after E. multilocularis crude antigen stimulation significantly decreased to (0.326 ± 0.106) and (0.315 ± 0.076), respectively (t = 6.359, 9.059; both P < 0.05). In vivo experiments showed that the hepatic indices, splenic indices, serum AST levels and liver HYP contents of infection group were (4.366 ± 0.284) %, (5.129 ± 1.114) mg/g, (22.194 ± 1.509) U/L, and (21.743 ± 2.503) × 10-2 μg/mg respectively, which were higher than (3.389 ± 0.045) %, (2.031 ± 0.165) mg/g, (17.355 ± 0.574) U/L and (9.330 ± 1.519) × 10-2 μg/mg in the control group (t = 3.393, 2.752, 2.616, 4.549; all P < 0.05). The serum AST levels of mice in the HaF treatment group at doses of 0.5, 1.0, and 2.0 g/(kg·d), the ABZ treatment group, and the combined ABZ + HaF treatment group were (17.375 ± 0.746), (15.411 ± 1.338), (17.057 ± 1.066), (16.190 ± 1.559), (14.637 ± 1.888) U/L, respectively, lower than those in infection group (t = 2.863, 3.362, 2.838, 2.717, 3.002; all P < 0.05). Among the treatment groups, the HaF treatment group at a dosage of 1.0 g/(kg•d) showed the most significant reduction in serum AST levels. There were no significant differences in hepatic/splenic indices and HYP content in liver tissue between the five treatment groups and the infection group (all P > 0.05). Western blotting results showed that the relative expression level of α-SMA protein in the liver tissue of mice in the 1.0 g/(kg•d) HaF treatment group was 0.818 ± 0.195, and the relative expression level of collagen Ⅰ in the liver tissue of mice in the combined treatment group of ABZ and HaF was 0.799 ± 0.167, both lower than those in the infected group (1.668 ± 0.131, 1.341 ± 0.141) (t = 3.619, 2.486; P < 0.05). The results of HE staining and Masson staining demonstrated that the fibrotic tissue area in the ABZ + HaF combined treatment group was (6.184 ± 1.951)%, which was significantly reduced compared to (19.916 ± 2.046)% in the infection group (t = 4.703, P < 0.01), indicating a notable improvement in liver fibrosis. Conclusion Zhuang medicine HaF demonstrates the ability to attenuate hepatic fibrosis induced by E. multilocularis infection both in vitro and in vivo. It also provides an experimental basis for HaF as a novel therapeutic agent for treatment of alveolar echinococcosis.

Cite this article

LI Jiajing , HUANG Wenjun , CAO Deping . Treatment effect of Zhuang medicine Herba abri formula on hepatic fibrosis induced by Echinococcus multilocularis infection[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2024 , 42(5) : 573 -581 . DOI: 10.12140/j.issn.1000-7423.2024.05.003

References

[1] Wang MM, An XQ, Zhou HQ, et al. Research progress in hepatic alveolar echinococcosis leading to cirrhosis[J]. Chin J Zoonoses, 2023, 39(11): 1130-1135. (in Chinese)
  (王苗苗, 安秀青, 周鸿乾, 等. 肝多房棘球蚴病导致肝硬化的研究进展[J]. 中国人兽共患病学报, 2023, 39(11): 1130-1135.)
[2] Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: advances in the 21st century[J]. Clin Microbiol Rev, 2019, 32(2): e00075-e00018.
[3] Woolsey ID, Miller AL. Echinococcus granulosus sensu lato and Echinococcus multilocularis: a review[J]. Res Vet Sci, 2021, 135: 517-522.
[4] Kern P, Menezes da Silva A, Akhan O, et al. The echinococcoses: diagnosis, clinical management and burden of disease[J]. Adv Parasitol, 2017, 96: 259-369.
[5] Cui ZY, Ye GB, Yu WH, et al. Progress of researches on albendazole for treatment of alveolar echinococcosis[J]. Chin J Schisto Control, 2023, 35(1): 104-110. (in Chinese)
  (崔紫烟, 冶赓博, 于文昊, 等. 阿苯达唑治疗多房棘球蚴病研究进展[J]. 中国血吸虫病防治杂志, 2023, 35(1): 104-110.)
[6] Lundstr?m-Stadelmann B, Rufener R, Ritler D, et al. The importance of being parasiticidal: an update on drug development for the treatment of alveolar echinococcosis[J]. Food Waterborne Parasitol, 2019, 15: e00040.
[7] Fabbri J, Pensel PE, Albani CM, et al. Drug repurposing for the treatment of alveolar echinococcosis: in vitro and in vivo effects of silica nanoparticles modified with dichlorophen[J]. Parasitology, 2019, 146(13): 1620-1630.
[8] Liu CC, Fan HN, Guan L,et al. In vivo and in vitro efficacy of crocin against Echinococcus multilocularis[J]. Parasit Vectors, 2021, 14(1): 364.
[9] Chen KK, Nong YX, Guo ZH, et al. Analysis of body composition and metabolic pathway of aqueous extract of Abrus cantonensis after gastric perfusion in rats[J]. China Pharm, 2024, 35(13): 1576-1581. (in Chinese)
  (陈奎奎, 农雨欣, 郭忠会, 等. 鸡骨草水提物灌胃大鼠后的体内成分及代谢途径分析[J]. 中国药房, 2024, 35(13): 1576-1581.)
[10] Zhang ML, Wu FF, Tan ZE, et al. Research progress of Herba Abri capsule and its clinical application[J]. Guangxi Med J, 2021, 43(24): 2981-2984. (in Chinese)
  (张孟丽, 吴芳芳, 谭栀恩, 等. 鸡骨草胶囊及其临床应用的研究进展[J]. 广西医学, 2021, 43(24): 2981-2984.)
[11] Li TP, Wu FF, Sun H, et al. Exploring the mechanism of the Abrus cantoniensis in the treatment of hepatitis B based on network pharmacology and molecular docking[J]. Drugs Clin, 2022, 37(1): 33-41. (in Chinese)
  (李太平, 吴芳芳, 孙晖, 等. 基于网络药理学和分子对接探究壮药鸡骨草治疗乙型肝炎的作用机制[J]. 现代药物与临床, 2022, 37(1): 33-41.)
[12] Li TP, Zhang ML, Tan ZE, et al. Rapid characterization of the constituents in Jigucao capsule using ultra high performance liquid chromatography with quadrupole time-of-flight mass spectrometry[J]. J Sep Sci, 2022, 45(3): 677-696.
[13] Li LZ, Tu YL, Dai XJ, et al. The effect of Abrus cantoniensis hance on liver damage in mice[J]. Ecotoxicol Environ Saf, 2023, 266: 115560.
[14] Wu QY. Therapeutic effect of Jigucao capsule on immune liver fibrosis in rats[J]. Guide China Med, 2010, 8(26): 46-48. (in Chinese)
  (吴茜玉. 鸡骨草胶囊对大鼠免疫性肝纤维化的治疗作用[J]. 中国医药指南, 2010, 8(26): 46-48.)
[15] Liu YM, Tian FM, Shan JY, et al. Kupffer cells: important participant of hepatic alveolar echinococcosis[J]. Front Cell Infect Microbiol, 2020, 10: 8.
[16] Zhang CY, Yuan WG, He P, et al. Liver fibrosis and hepatic stellate cells: etiology, pathological hallmarks and therapeutic targets[J]. World J Gastroenterol, 2016, 22(48): 10512-10522.
[17] Barry AE, Baldeosingh R, Lamm R, et al. Hepatic stellate cells and hepatocarcinogenesis[J]. Front Cell Dev Biol, 2020, 8: 709.
[18] Zhao L, Li J, Mo G, et al. Recombinant protein EBI3 attenuates Clonorchis sinensis-induced liver fibrosis by inhibiting hepatic stellate cell activation in mice[J]. Parasit Vectors, 2023, 16(1): 246.
[19] Cao DP, Shamsan E, Jiang BF, et al. Structural changes and expression of hepatic fibrosis-related proteins in coculture of Echinococcus multilocularis protoscoleces and human hepatic stellate cells[J]. Parasit Vectors, 2021, 14(1): 593.
[20] Cao DP, Li JJ, Song MW, et al. Experimental observation on the changes of hepatic stellate cells stimulated in vitro with tissue protein of Echinococcus multilocularis[J]. Chin J Parasitol Parasit Dis, 2023, 41(4): 440-445. (in Chinese)
  (曹得萍, 李嘉静, 宋梦微, 等. 多房棘球蚴组织蛋白体外刺激肝星状细胞变化的实验观察[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(4): 440-445.)
[21] Xu XL, Qian XY, Gao CC, et al. Advances in the pharmacological treatment of hepatic alveolar echinococcosis: from laboratory to clinic[J]. Front Microbiol, 2022, 13: 953846.
[22] Dang ZS, Oku Y, Zhou XN,et al. In vitro inhibitive effect of the anticancer drug sorafenib on Echinococcus multilocularis larvae[J]. Chin J Parasitol Parasit Dis, 2017, 35(5): 417-422. (in Chinese)
  (党志胜, 奥祐三郎, 周晓农, 等. 抗癌药物索拉非尼体外抗多房棘球蚴的效果评价[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(5): 417-422.)
[23] Xiao SH, Xue J, Tanner M, et al. Artemether, artesunate, praziquantel and tribendimidine administered singly at different dosages against Clonorchis sinensis: a comparative in vivo study[J]. Acta Trop, 2008, 106(1): 54-59.
[24] Zhang FB, Hu CH, Cheng SL, et al. The investigation of the effect and mechanism of Sophora moorcroftiana alkaloids in combination with albendazole on echinococcosis in an experimental rats model[J]. Evid Based Complement Alternat Med, 2018, 2018: 3523126.
[25] Tan XW, Yu XF, Jiang HJ, et al. Inhibitory effect of xanthohumol on the growth of Echinococcus multilocularis metacestode in the liver of mice[J]. Chin J Parasitol Parasit Dis, 2021, 39(3): 304-310. (in Chinese)
  (谭小武, 俞晓凡, 姜慧娇, 等. 黄腐酚对小鼠肝多房棘球蚴生长的抑制作用[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(3): 304-310.)
[26] Liang G, Wei KD. Protective effect of ethanol extract of Abrus cantonensis on carbon tetrachloride-induced liver injury in rats[J]. J Guangxi Med Univ, 2012, 29(6): 852-854. (in Chinese)
  (梁耿, 韦凯东. 鸡骨草醇提物对四氯化碳诱导肝损伤大鼠的保护作用[J]. 广西医科大学学报, 2012, 29(6): 852-854.)
[27] Qin YS, Huang ZM, He P, et al. Protective effects of compound Jigucao capsule against acute chemical liver injury in mice[J]. Chin J Clin Rehabil, 2006, 10(23): 142-143. (in Chinese)
  (覃永生, 黄志明, 何萍, 等. 复方鸡骨草胶囊对小鼠急性化学性肝损伤的保护作用[J]. 中国临床康复, 2006, 10(23): 142-143.)
[28] Lei QY. Effect of Jigucao capsule adjuvant therapy on liver fibrosis in patients with nonalcoholic fatty liver disease[J]. Shenzhen J Integr Tradit Chin West Med, 2018, 28(10): 37-39. (in Chinese)
  (雷清瑶. 鸡骨草胶囊辅助治疗对非酒精性脂肪肝患者肝纤维化的影响[J]. 深圳中西医结合杂志, 2018, 28(10): 37-39.)
Outlines

/

〈 〉